Background Deposition of tau aggregates is a pathological hallmark of Alzheimer's disease
that is closely linked both spatially and temporally to emergence of neurodegeneration and …

Biomarkers for neurodegenerative diseases are needed to improve the diagnostic workup in
the clinic but also to facilitate the development and monitoring of effective disease-modifying …

Abstract The National Institute on Aging and the Alzheimer's Association convened three
separate work groups in 2011 and single work groups in 2012 and 2018 to create …

A major unanswered question in the dementia field is whether cognitively unimpaired
individuals who harbor both Alzheimer's disease neuropathological hallmarks (that is …

Summary In 2018, the US National Institute on Aging and the Alzheimer's Association
proposed a purely biological definition of Alzheimer's disease that relies on biomarkers …

Extracellular neuritic plaques composed of amyloid‑β (Aβ) protein and intracellular
neurofibrillary tangles containing phosphorylated tau protein are the two hallmark proteins of …

Patients with Alzheimer's disease (AD) present with both extracellular amyloid-β (Aβ)
plaques and intracellular tau-containing neurofibrillary tangles in the brain. For many years …

Importance Tau positron emission tomography (PET) tracers have proven useful for the
differential diagnosis of dementia, but their utility for predicting cognitive change is unclear …

The shared role of amyloid-β (Aβ) deposition in cerebral amyloid angiopathy (CAA) and
Alzheimer disease (AD) is arguably the clearest instance of crosstalk between …

Alzheimer's disease is a neurodegenerative disease that accounts for most of the 50-million
dementia cases worldwide in 2018. A large amount of evidence supports the amyloid …